Concepedia

Richard C. Chao

RC

53

Publications

8.1K

Citations

33

H-Index

1992

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Dana-Farber Cancer Institute

Sarah Cannon

Tennessee Oncology

Richard C. Chao is an author at Mirati Therapeutics (United States) specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1992–2023

53

Publications

53

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation

Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2022 · 886 citations · Full text

Institutional implementation of clinical tumor profiling on an unselected cancer population

Lynette M. Sholl, T. Khanh, Priyanka Shivdasani et al. · JCI Insight · 2016 · 434 citations · Full text

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Mark A. Socinski, Silvia Novello, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2008 · 320 citations · Full text

Rows per page

1–5 of 53